A growth hormone secretagogue is any compound that causes the anterior pituitary to release growth hormone. Research peptides in this class work through one of two receptors: GHRH analogs such as sermorelin, CJC-1295 and tesamorelin activate the GHRH receptor, and growth hormone-releasing peptides (GHRPs) such as GHRP-6, GHRP-2 and ipamorelin activate the ghrelin receptor, GHS-R1a. The two receptors use different G proteins and second messengers, which is why the classes are studied both separately and side by side.
This primer defines the terms, traces how each class was discovered, lays out the members with their sequences and regulatory status, and compares the two receptor systems.
What the term means
In its broadest sense, "secretagogue" means a substance that causes a cell to secrete something. A growth hormone secretagogue causes somatotrophs, the growth hormone-producing cells of the anterior pituitary, to release growth hormone.
In the endocrinology literature the phrase has a narrower history. It was first used for a group of synthetic compounds, beginning with small peptides in the 1980s, that released growth hormone through a receptor that was then unknown. When that receptor was cloned in 1996, it was named the growth hormone secretagogue receptor, GHS-R. Its natural ligand turned out to be ghrelin. So in older papers "GHS" usually means a ghrelin-receptor agonist, and GHRH analogs are discussed separately.
Supplier catalogs and review articles now tend to use the broad sense, covering both receptor classes. This post does the same but keeps the two clearly apart.
Three inputs to the somatotroph
Growth hormone secretion is controlled by at least three hormonal inputs acting on the somatotroph:
| Input | Source | Receptor | Effect on GH release |
|---|---|---|---|
| GHRH | Hypothalamus | GHRH receptor (Gs-coupled) | Stimulates |
| Somatostatin | Hypothalamus | Somatostatin receptors | Inhibits |
| Ghrelin | Mainly stomach | GHS-R1a (Gq-coupled) | Stimulates |
Synthetic secretagogues plug into the two stimulatory inputs. Somatostatin still acts on the same cells: in the 1984 paper that introduced GHRP-6, Bowers and colleagues found that somatostatin-14 and somatostatin-28 both inhibited the growth hormone response to the new hexapeptide.
How each class was found
The two classes were discovered from opposite directions. GHRH was a natural hormone isolated first and then trimmed and modified by chemists. The GHRPs were synthetic compounds first, and their natural counterpart was found fifteen years later.
| Year | Event |
|---|---|
| 1982 | Human GHRH isolated from pancreatic tumors that caused acromegaly; 44-residue sequence reported (Guillemin et al.). GRF(1-29)-NH2 shown to be fully active in vitro (Spiess et al.) |
| 1984 | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6) described as a synthetic hexapeptide that releases growth hormone without releasing LH, FSH, TSH or prolactin (Bowers et al.) |
| 1986 | Plasma DPP-4 shown to inactivate GHRH by removing its N-terminal Tyr-Ala (Frohman et al.) |
| 1996 | The GHS receptor cloned from pituitary and hypothalamus (Howard et al., Merck) |
| 1998 | Ipamorelin described as the first selective GHRP-receptor agonist (Raun et al., Novo Nordisk) |
| 1999 | Ghrelin identified as the natural ligand of GHS-R: a 28-residue peptide with an n-octanoyl group on Ser3 (Kojima et al.) |
| 2005 | CJC-1295, an albumin-binding GHRH(1-29) analog, described (Jetté et al., ConjuChem) |
| 2010 | Tesamorelin approved by the FDA as Egrifta |
| 2017 | Macimorelin approved by the FDA as Macrilen, a diagnostic agent |
Class 1: GHRH receptor agonists
These are all built on the N-terminal part of human GHRH, since the first 29 residues carry the activity. They differ in how they deal with DPP-4, which removes Tyr1-Ala2 and destroys activity.
| Compound | Structure | Stabilizing feature | Status |
|---|---|---|---|
| Sermorelin | GHRH(1-29)-NH2, unmodified | None | Approved in the US as Geref; withdrawn 2009 for business reasons |
| CJC-1295 without DAC (mod GRF 1-29) | GHRH(1-29)-NH2 with D-Ala2, Gln8, Ala15, Leu27 | D-Ala2 resists DPP-4 | Never approved |
| CJC-1295 with DAC | As above, plus Lys30 carrying a maleimidopropionyl group | D-Ala2 plus covalent binding to albumin Cys34 | Never approved |
| Tesamorelin | GHRH(1-44)-NH2 with trans-3-hexenoyl on Tyr1 | N-terminal acyl cap blocks DPP-4 | Approved (Egrifta) |
The GHRH receptor (UniProt Q02643) is a 423-residue class B GPCR. UniProt describes it as coupled to G proteins that activate adenylyl cyclase, stimulating somatotroph growth, growth hormone gene transcription and growth hormone secretion. The individual molecules are covered in more depth in Sermorelin vs Ipamorelin, CJC-1295 vs Ipamorelin and our tesamorelin profile.
Class 2: ghrelin receptor agonists
The second class began with Cyril Bowers's work on small synthetic peptides and grew into a family of hexapeptides and pentapeptides, then into non-peptide and peptidomimetic compounds.
| Compound | Sequence or type | Notes |
|---|---|---|
| GHRP-6 | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 | Described in 1984 (Bowers et al.) |
| GHRP-2 (pralmorelin) | D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 | Hexapeptide; PubChem lists it as pralmorelin |
| Ipamorelin | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Pentapeptide; derived by removing the central Ala-Trp of GHRP-1 |
| MK-0677 | Non-peptide small molecule | Listed by UniProt among non-peptide GHS-R ligands |
| Macimorelin | Peptidomimetic small molecule | FDA-approved (Macrilen) for the diagnosis of adult growth hormone deficiency |
| Ghrelin | 28 residues, n-octanoyl on Ser3 | The natural ligand |
Several patterns run through the synthetic members: D-amino acids, bulky aromatic side chains such as tryptophan and 2-naphthylalanine, a basic lysine near the C-terminus, and a C-terminal amide. Unnatural residues of this kind make short peptides harder for proteases to recognize.
The ghrelin receptor, GHS-R1a (UniProt Q92847), is a 366-residue class A GPCR. UniProt notes that it couples to Gq proteins and mediates production of diacylglycerol and IP3, and that besides ghrelin it binds GHRPs such as GHRP-6 and non-peptide secretagogues such as MK-0677. The receptor is also active in the absence of any ligand, and it is expressed in the pituitary, the hypothalamus and more widely in the brain.
Selectivity within the GHRPs
Not every ghrelin receptor agonist behaves the same way outside the somatotroph. Raun and colleagues compared ipamorelin with GHRP-6 and GHRP-2 in conscious swine in 1998. None of the three changed FSH, LH, prolactin or TSH. GHRP-6 and GHRP-2 raised ACTH and cortisol, while ipamorelin did not raise them above the levels seen after GHRH, even at more than 200 times the level needed for half-maximal growth hormone release. The authors called ipamorelin the first GHRP-receptor agonist with a growth hormone selectivity similar to GHRH's.
For experimental design, that means the choice of GHRP matters. A study that wants to isolate growth hormone release from adrenal-axis responses has reason to prefer ipamorelin; one that is studying those responses has reason to include GHRP-6 or GHRP-2.
The two receptor systems compared
| Feature | GHRH receptor | Ghrelin receptor (GHS-R1a) |
|---|---|---|
| UniProt entry (human) | Q02643 | Q92847 |
| Length | 423 residues | 366 residues |
| GPCR family | Class B (secretin family) | Class A (rhodopsin family) |
| Main G protein | Gs | Gq/11 |
| Second messengers | Cyclic AMP | IP3, diacylglycerol, intracellular calcium |
| Natural ligand | GHRH (44 residues) | Ghrelin (28 residues, acylated) |
| Main tissue for GH release | Pituitary somatotrophs | Pituitary somatotrophs and hypothalamus |
| Research peptides | Sermorelin, CJC-1295, tesamorelin | GHRP-6, GHRP-2, ipamorelin |
Because the two receptors converge on the same cell through different signaling routes, antagonists for each can be used to assign a response to one pathway. Raun's group used exactly that approach to show that ipamorelin acts through the GHRP receptor rather than the GHRH receptor. It is also the reason research catalogs, including ours, list blends that pair one compound from each class.
Downstream: growth hormone and IGF-1
Growth hormone itself acts on receptors in many tissues, and some of its actions are mediated by insulin-like growth factor 1, produced in the liver and in peripheral tissues. Secretagogue studies therefore often measure IGF-1 alongside growth hormone. Engineered IGF-1 analogs act at the very end of the axis; our profile of IGF-1 LR3 covers one of them.
Regulatory status at a glance
| Compound | US regulatory status |
|---|---|
| Sermorelin | Formerly approved (Geref); withdrawn effective 2009, not for reasons of safety or effectiveness |
| Tesamorelin | Approved as Egrifta (2010) for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy |
| Macimorelin | Approved as Macrilen (2017) for the diagnosis of adult growth hormone deficiency |
| CJC-1295 (either form) | Investigational; never approved |
| Ipamorelin | Investigational; a Phase 2 trial in postoperative ileus was completed |
| GHRP-6, GHRP-2 | Not approved by the FDA |
Research-grade material is a separate matter from any approved product. Anhydrolabs supplies these compounds for laboratory research only, not for human or veterinary diagnosis, treatment, or consumption; the research-use page explains the terms.
Working with secretagogue peptides
The two classes differ in size by almost an order of magnitude, from about 712 g/mol for ipamorelin to about 5,136 g/mol for tesamorelin, so equal mass concentrations give very different molar concentrations. Compare them in molar units. The GHRH-derived peptides mostly carry Met27, which oxidizes to a +16 Da sulfoxide; CJC-1295 replaces it with leucine. The GHRPs are short and contain no methionine or cysteine.
All of these ship as lyophilized powders. Our guides on how to reconstitute peptides and how long peptides last cover preparation and stability, and the storage and handling page lists the conditions we use.
Anhydrolabs supplies ipamorelin, sermorelin, tesamorelin and CJC-1295 (no DAC) as lyophilized powders in vacuum-sealed vials, also available as 10-vial kits.


